The epigenetics company Epiqmax is now part of the Berlin-based provider of longevity solutions Moleqlar. Its product range is designed to combat the signs of aging and improve health indicators at the molecular level.
Epiqmax was founded in 2018 as a spin-off from LMU and specializes in proteomic analysis and epigenetics. The company offers an epigenetic saliva test that provides deeper insights into how the body functions at the cellular level. In the third quarter of 2023 The biotech startup had to file for bankruptcy.
Maximilian Griessinger, Managing Director of Moleqlar, says:
"The acquisition of Epiqmax is a strategic move for Moleqlar, and we look forward to welcoming their team of experts and advanced technologies to our company. The integration of Epiqmax's proteomic analysis technologies will significantly expand our analytical and product development capabilities."
Moritz Völker-Albert, CEO of the newly founded Moleqlar Analytics GmbH (formerly Epiqmax), comments:
"Epiqmax is excited to become part of the Moleqlar team. Our technical capabilities in proteomic analysis and histone modification quantification will significantly enhance Moleqlar's capabilities and help us leverage epigenetics to sustainably improve people's lives through advanced, personalized healthcare solutions."
